litlas
Log inCreate account

Amit M. Oza

Active 1989–2025

Also published as
Amit M Oza
222
Papers
46,248
Citations
101
h-index
215
i10-index

Citations

Citations per year for Amit M. Oza1992: 2 citations1993: 1 citations1994: 2 citations1995: 2 citations1996: 3 citations1997: 6 citations1998: 5 citations1999: 2 citations2000: 16 citations2001: 13 citations2002: 14 citations2003: 30 citations2004: 32 citations2005: 60 citations2006: 77 citations2007: 108 citations2008: 140 citations2009: 132 citations2010: 157 citations2011: 136 citations2012: 192 citations2013: 215 citations2014: 254 citations2015: 248 citations2016: 345 citations2017: 385 citations2018: 422 citations2019: 1,721 citations2020: 2,299 citations2021: 2,147 citations2022: 2,001 citations2023: 1,616 citations2024: 2,334 citations2025: 1,152 citations2026: 29 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,639 citing papers, 22.8% of this breakdownChina: 1,909 citing papers, 12% of this breakdownUnited Kingdom: 1,184 citing papers, 7.4% of this breakdownItaly: 935 citing papers, 5.9% of this breakdownCanada: 823 citing papers, 5.2% of this breakdownFrance: 687 citing papers, 4.3% of this breakdownGermany: 664 citing papers, 4.2% of this breakdownSpain: 524 citing papers, 3.3% of this breakdownJapan: 467 citing papers, 2.9% of this breakdownAustralia: 459 citing papers, 2.9% of this breakdownNetherlands: 386 citing papers, 2.4% of this breakdownSouth Korea: 320 citing papers, 2% of this breakdown
0%22.8%Other 24.7%

Institutions

Fields

  • Medicine64.4%
  • Biochemistry, Genetics and Molecular Biology28.1%
  • Immunology and Microbiology2.7%
  • Mathematics0.8%
  • Materials Science0.7%
  • Computer Science0.5%
  • Other2.8%

Topics

  • Ovarian cancer diagnosis and treatment8.8%
  • PARP inhibition in cancer therapy8.4%
  • DNA Repair Mechanisms3.2%
  • Endometrial and Cervical Cancer Treatments2.8%
  • Cancer Genomics and Diagnostics2.5%
  • BRCA gene mutations in cancer2.2%
  • Other72.1%

Coauthors

All papers

Open in search
  1. Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Authors: Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Paul DiSilvestro - New England Journal of Medicine 2018 cited by 2,839

  2. Epithelial ovarian cancer

    Authors: Stéphanie Lheureux, Charlie Gourley, Ignace Vergote, Amit M. Oza - The Lancet 2019 cited by 1,940

  3. Epithelial ovarian cancer: Evolution of management in the era of precision medicine

    Authors: Stéphanie Lheureux, Marsela Braunstein, Amit M. Oza - CA A Cancer Journal for Clinicians 2019 cited by 1,471

  4. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

    Authors: Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, Amit M. Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A. Ledermann, Domenica Lorusso, Ignace Vergote, Noa Ben-Baruch, Christian Marth, Radosław Mądry, René dePont Christensen, Jonathan S. Berek, Anne Dørum, Anna V. Tinker, Andreas du Bois, Antonio González-Martı́n, Philippe Follana, Benedict B. Benigno, Per Rosenberg, Lucy Gilbert, B.J. Rimel, Joseph Buscema, John Balser, Shefali Agarwal, Ursula A. Matulonis - New England Journal of Medicine 2016 cited by 2,458

  5. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle, Val Gebski, Richard T. Penson, Amit M. Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata, Michael Friedländer, Nicoletta Colombo, Philipp Harter, Keiichi Fujiwara, Isabelle Ray‐Coquard, Susana Banerjee, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Patricia Pautier, Jacob Korach, Tomasz Huzarski, Tomasz Byrski, Patricia Pautier, Michael Friedländer, Philipp Harter, Nicoletta Colombo, Sandro Pignata, Giovanni Scambia, Maria Ornella Nicoletto, Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan A. Davidson and 21 more - The Lancet Oncology 2017 cited by 1,863

  6. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Robert L. Coleman, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Léary, Robert W. Holloway, Margarita Amenedo, Peter C.C. Fong, Jeffrey C. Goh, David M. O’Malley, Deborah K. Armstrong, Jesús García-Donás, Elizabeth M. Swisher, Anne Floquet, Gottfried E. Konecny, Iain A. McNeish, Clare L. Scott, T. Cameron, Lara Maloney, Jeff Isaacson, Sandra Goble, Caroline A. Grace, Thomas C. Harding, Mitch Raponi, James Sun, Kevin Lin, Heidi Giordano, Jonathan A. Ledermann, Martin Buck, Andrew Dean, Michael Friedländer, Jeffrey C. Goh, Paul R. Harnett, Ganessan Kichenadasse, Clare L. Scott, Hannelore Denys, Luc Dirix, Ignace Vergote, Laurie Elit, Prafull Ghatage, Amit M. Oza, Marie Plante, Diane Provencher, Johanne I. Weberpals, Stephen Welch, Anne Floquet, Laurence Gladieff, Florence Joly, Alexandra Léary, Alain Lortholary, Jean‐Pierre Lotz, Jacques Médioni, Olivier Trédan, Benoît You, Ayşe Balat, Claudia Hänle, Petra Krabisch, Tanja Neunhöffer, Martin Pölcher, Pauline Wimberger, A Amit, Svetlana Kovel, Michelle Leviov, Tamar Safra, Ronnie Shapira‐Frommer, Salomon M. Stemmer, Alessandra Bologna, Nicoletta Colombo, Domenica Lorusso, Sandro Pignata, Roberto Sabbatini, Giovanni Scambia, Stefano Tamberi, Claudio Zamagni, Peter C.C. Fong, Anne O’Donnell, Margarita Amenedo, A. Casado Herráez, Jesús García-Donás, E.M. Guerra, Ana Oaknin, Isabel Palacio, Ignacio Romero, A Sanchez, Susana Banerjee, Andrew R. Clamp, Yvette Drew, Hani Gabra, D Jackson, JA Ledermann, Iain A. McNeish, C. A. Parkinson, Melanie Powell, Carol Aghajanian and 17 more - The Lancet 2017 cited by 1,704

  7. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    Authors: Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, John McNamara, Elizabeth Lowe, Mei-Lin Ah-See, Kathleen N. Moore, on behalf of the SOLO1 Investigators - Journal of Clinical Oncology 2022 cited by 475

  8. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

    Authors: Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon, Jung‐Yun Lee, Jessica Thomes Pepin, Michael Sundborg, Ayelet Shai, Joseph de la Garza, Shin Nishio, Michael A. Gold, Ke Wang, Kristi McIntyre, Todd Tillmanns, Stephanie V. Blank, Jihong Liu, Michael McCollum, Fernando Contreras Mejía, Tadaaki Nishikawa, Kathryn P. Pennington, Zoltan Novak, Andréia Cristina de Melo, Jalid Sehouli, Dagmara Klasa-Mazurkiewicz, Christos Papadimitriou, Marta Gil-Martín, Birute Brasiuniene, Conor Donnelly, Paula Michelle del Rosario, Xiaochun Liu, Els Van Nieuwenhuysen, Sophia Frentzas, Ganessan Kichendasse, Bo Gao, Tarek Meniawy, Linda Mileshkin, Gary Richardson, Felicia Roncolato, Jean‐François Baurain, Maryam Bourhaba, Eveline Cuypere, Philip R. Debruyne, Hannelore Denys, Frédéric Forget, Brigitte Honhon, E. Joosens, Els Van Nieuwenhuysen, Vanessa da Costa Miranda, Andréia Cristina de Melo, Joao Daniel Guedes, Charles Andreé Joseph de Pádua, Nicolas Lazaretti, Carolina Martins Vieira, André Mattar, Daniela Neves Palmeiro, Christina Pimentel Oppermann Kussler, Pedro Emanuel Rubini Liedke, João Soares Nunes, Katsuki Arima Tiscoski, Allan Covens, Lara De Guerké, Prafull Ghatage, Lucy Gilbert, Susie Lau, Amit M. Oza, Diane Provencher, Omar Touhami, Congzhu Li, Danbo Wang, Ge Lou, Zhu Genhai, Guiling Li, Shi Hong, Hong Zheng, Wen Hongwu, Jihong Liu, Jing Wang, Ke Wang, Jiang Kui, Li Li, Wang Li, Hao Min, Qi Zhou, Gao Qinglei, Sihai Liao, Zhang Songling, Zhao Weidong, Xiaohua Wu, Wuliang Wang, Rutie Yin, Cheng Ying, Yu Zhang, Liang Zhiqing, Fernando Contreras Mejía, Ángel Luis Martín de Francisco Hernández, Carolina Ortiz Lopez, Carlos Javier Pacheco, Pedro Luis Ramos Guette, Jaime Rendon Pereira, Julian Rivera Diaz, Tomás Sánchez Villegas and 156 more - Journal of Clinical Oncology 2023 cited by 331

  9. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study

    Authors: Éric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A. Ledermann, Amit M. Oza, Rebecca Kristeleit, Isabelle-Laure Ray-Coquard, Gary Richardson, Cristiana Sessa, Kan Yonemori, Susana Banerjee, Alexandra Léary, Anna V. Tinker, Kyung Hae Jung, Radosław Mądry, Sang‐Yoon Park, Charles Anderson, Fabian Zohren, Ross Stewart, Caimiao Wei, Samuel S. Dychter, Bradley J. Monk - The Lancet Oncology 2021 cited by 405

  10. A Phase 3 Trial of Bevacizumab in Ovarian Cancer

    Authors: Timothy Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A. Ledermann, Éric Pujade-Lauraine, Gunnar B. Kristensen, Mark S. Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder, Andreas du Bois, Jalid Sehouli, Rainer Kimmig, Anne Stähle, Fiona Collinson, Sharadah Essapen, Charlie Gourley, Alain Lortholary, Frédèric Selle, Mansoor R. Mirza, Arto Leminen, Marie Plante, Dan Stark, Wendi Qian, Mahesh Parmar, Amit M. Oza - New England Journal of Medicine 2011 cited by 2,152

  11. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

    Authors: Kathleen N. Moore, Amit M. Oza, Nicoletta Colombo, Ana Oaknin, Giovanni Scambia, Domenica Lorusso, Gottfried E. Konecny, Susana Banerjee, Conleth G. Murphy, János L. Tanyi, Hal W. Hirte, Jason Konner, Peter Lim, Monica Prasad-Hayes, Bradley J. Monk, Patricia Pautier, Jiao Wang, Anna Berkenblit, Ignace Vergote, Michael J. Birrer - Annals of Oncology 2021 cited by 292

  12. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

    Authors: Elizabeth M. Swisher, Kevin Lin, Amit M. Oza, Clare L. Scott, Heidi Giordano, James Sun, Gottfried E. Konecny, Robert L. Coleman, Anna V. Tinker, David M. O’Malley, Rebecca Kristeleit, Ling Ma, Katherine M. Bell‐McGuinn, James D. Brenton, Janiel M. Cragun, Ana Oaknin, Isabelle Ray‐Coquard, Maria I. Harrell, Elaina Mann, Scott H. Kaufmann, Anne Floquet, Alexandra Léary, Thomas C. Harding, Sandra Goble, Lara Maloney, Jeff Isaacson, Andrew R. Allen, Lindsey Rolfe, Roman Yelensky, Mitch Raponi, Iain A. McNeish - The Lancet Oncology 2016 cited by 1,200

  13. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial

    Authors: Camilla Zimmermann, Nadia Swami, Monika K. Krzyzanowska, Breffni Hannon, Natasha B. Leighl, Amit M. Oza, Malcolm J. Moore, Anne Rydall, Gary Rodin, Ian F. Tannock, Allan Donner, Christopher Lo - The Lancet 2014 cited by 1,796

  14. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: Andrés Poveda, Anne Floquet, Jonathan A. Ledermann, Rebecca Asher, Richard T. Penson, Amit M. Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Michael Friedländer, Alessandra Baldoni, Tjoung-Won Park-Simon, Kenji Tamura, Gabe S. Sonke, Alla Lisyanskaya, Jae‐Hoon Kim, Elias Abdo Filho, Tsveta Milenkova, Elizabeth Lowe, Philip Rowe, Ignace Vergote, Éric Pujade-Lauraine, Jacob Korach, Tomasz Huzarski, Tomasz Byrski, Patricia Pautier, Michael Friedländer, Philipp Harter, Nicoletta Colombo, Sandro Pignata, Giovanni Scambia, Maria Ornella Nicoletto, Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano and 23 more - The Lancet Oncology 2021 cited by 416

  15. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial

    Authors: Bradley J. Monk, Nicoletta Colombo, Amit M. Oza, Keiichi Fujiwara, Michael J. Birrer, Leslie M. Randall, Elena Poddubskaya, Giovanni Scambia, Yaroslav Shparyk, Myong Cheol Lim, Snehalkumar M Bhoola, Joohyuk Sohn, Kan Yonemori, Ross Stewart, Xiaoxi Zhang, Julia Perkins Smith, Carlos Linn, Jonathan A. Ledermann - The Lancet Oncology 2021 cited by 284

  16. BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

    Authors: Kevin Lin, Maria I. Harrell, Amit M. Oza, Ana Oaknin, Isabelle Ray‐Coquard, Anna V. Tinker, Elena Helman, Marc R. Radke, Carmen Say, Lan-Thanh Vo, Elaina Mann, Jeffrey D. Isaacson, Lara Maloney, David M. O’Malley, Setsuko K. Chambers, Scott H. Kaufmann, Clare L. Scott, Gottfried E. Konecny, Robert L. Coleman, James Sun, Heidi Giordano, James D. Brenton, Thomas C. Harding, Iain A. McNeish, Elizabeth M. Swisher - Cancer Discovery 2018 cited by 432

  17. Heterogeneity and treatment landscape of ovarian carcinoma

    Authors: Ana Veneziani, Eduardo González-Ochoa, Husam Alqaisi, Ainhoa Madariaga, Gita Bhat, Marjan Rouzbahman, Suku Sneha, Amit M. Oza - Nature Reviews Clinical Oncology 2023 cited by 193

  18. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

    Authors: Amit M. Oza, Adrian Cook, Jacobus Pfisterer, Andrew Embleton-Thirsk, Jonathan A. Ledermann, Éric Pujade-Lauraine, Gunnar B. Kristensen, Mark S. Carey, Philip Beale, Andrés Cervantes, Tjoung‐Won Park‐Simon, Gordon Rustin, Florence Joly, Mansoor Raza Mirza, Marie Plante, Michael Quinn, Andrés Poveda, Gordon C. Jayson, Dan Stark, Ann Marie Swart, Laura Farrelly, Richard Kaplan, Mahesh Parmar, Timothy Perren - The Lancet Oncology 2015 cited by 867

  19. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

    Authors: Kathleen N. Moore, Angeles Alvarez Secord, Melissa A. Geller, David S. Miller, Noelle Cloven, Gini F. Fleming, Andrea E. Wahner Hendrickson, Masoud Azodi, Paul DiSilvestro, Amit M. Oza, Mihaela Cristea, Jonathan S. Berek, John K. Chan, B.J. Rimel, Daniela Matei, Yong Li, Kaiming Sun, Katarina Luptakova, Ursula A. Matulonis, Bradley J. Monk - The Lancet Oncology 2019 cited by 537

  20. openalex_id:w4226283539

    Authors: Susana Banerjee, Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Eileen Holmes, Elizabeth Lowe, Paul DiSilvestro cited by 185

  21. Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

    Authors: Olga Kondrashova, Minh Nguyen, Kristy Shield‐Artin, Anna V. Tinker, Nelson N.H. Teng, Maria I. Harrell, Michael J. Kuiper, Gwo‐Yaw Ho, Holly E. Barker, Maria Jasin, Rohit Prakash, Elizabeth M. Kass, Meghan R. Sullivan, Gregory J. Brunette, Kara A. Bernstein, Robert L. Coleman, Anne Floquet, Michael Friedländer, Ganessan Kichenadasse, David M. O’Malley, Amit M. Oza, James Sun, Liliane Robillard, Lara Maloney, David D.L. Bowtell, Heidi Giordano, Matthew J. Wakefield, Scott H. Kaufmann, Andrew D. Simmons, Thomas C. Harding, Mitch Raponi, Iain A. McNeish, Elizabeth M. Swisher, Kevin Lin, Clare L. Scott - Cancer Discovery 2017 cited by 417

  22. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

    Authors: Jean‐Sébastien Frenel, J.W. Kim, Nanda Aryal, Rebecca Asher, Dominique Berton, Laura Vidal, Patricia Pautier, Jonathan A. Ledermann, Richard T. Penson, Amit M. Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Nicoletta Colombo, Tjoung-Won Park-Simon, Kenji Tamura, Gabe S. Sonke, Alison Freimund, Chee Khoon Lee, Éric Pujade-Lauraine - Annals of Oncology 2022 cited by 154

  23. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

    Authors: Elizabeth M. Swisher, Tanya T. Kwan, Amit M. Oza, Anna V. Tinker, Isabelle Ray‐Coquard, Ana Oaknin, Robert L. Coleman, Carol Aghajanian, Gottfried E. Konecny, David M. O’Malley, Alexandra Léary, Diane Provencher, Stephen Welch, Lee-may Chen, Andrea E. Wahner Hendrickson, Ling Ma, Prafull Ghatage, Rebecca Kristeleit, Oliver Dorigo, Ashan Musafer, Scott H. Kaufmann, Julia A. Elvin, Douglas I. Lin, Setsuko K. Chambers, Erin Dominy, Lan-Thanh Vo, Sandra Goble, Lara Maloney, Heidi Giordano, Thomas Harding, Alexander Dobrovic, Clare L. Scott, Kevin Lin, Iain A. McNeish - Nature Communications 2021 cited by 205

  24. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial

    Authors: Rebecca Kristeleit, Alla Lisyanskaya, Alexander Fedenko, Mikhail Dvorkin, Andreia Cristina de Melo, Yaroslav Shparyk, Irina Rakhmatullina, Igor Bondarenko, Nicoletta Colombo, Valentyn Svintsitskiy, Luciano Biela, Marina Nechaeva, Domenica Lorusso, Giovanni Scambia, David Cibula, Róbert Póka, Ana Oaknin, Tamar Safra, Beata Mackowiak-Matejczyk, Ling Ma, Daleen Thomas, Kevin K Lin, Karen McLachlan, Sandra Goble, Amit M Oza - The Lancet Oncology 2022 cited by 143